Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses hair regrowth using oral minoxidil and RU58841, with visible baby hairs appearing after two months. One user questions the choice of RU58841 over finasteride.

RU58841 is being discussed as a hair loss treatment without using finasteride or dutasteride. Users are sharing their experiences and success with RU58841 alone.

The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.

The user cannot tolerate oral finasteride and is considering topical finasteride, minoxidil, microneedling, and RU58841 as alternative treatments for hair loss. They seek advice on whether these options are worth trying.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

The conversation discusses the anticipation for updates on GT20029, a potential hair loss treatment. Users also mention using Minoxidil, finasteride, and RU58841.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Users question effectiveness of HMI-115 and consider waiting longer for results.

The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.

The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.

L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

Pyluritamide and RU58841 are compared for effectiveness in addition to dutasteride for hair loss treatment. Reddit users report great results with RU58841, but data suggests pyluritamide may have better affinity.

RU58841 availability on Amazon is questioned for legitimacy. Users discuss its use alongside Minoxidil and Finasteride for hair loss treatment.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

The user is seeking advice on adding CB 03-01 to their hair loss treatment, which includes RU58841, Fluridil, Minoxidil, and Pantostin, but cannot use finasteride.

PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

The user reported progress in hair growth after 4 months using 0.5 mg finasteride and 2.5 mg minoxidil daily, and is considering adding RU58841 to block DHT on the scalp. They experienced side effects like reduced libido and mild erectile dysfunction, and take supplements like zinc, iron, fish oil, vitamin D, magnesium, and vitamin E.

The conversation is about obtaining pyrilutamide for hair loss treatment from China through a contact, with details on pricing and shipping. The user offers to facilitate the purchase and shipment for a small commission.

Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.

Treatments for hair loss, including microneedling (dermarolling and dermapen) and the use of minoxidil, finasteride, and RU58841. It provides detailed information about cost and usage of the various treatments, as well as potential side effects.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.